enGene (ENGN) Projected to Post Earnings on Thursday

enGene (NASDAQ:ENGN) will likely be releasing its Q2 2026 results before the market opens on Thursday, June 11th. Analysts expect enGene to post earnings of ($0.49) per share for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Friday, June 12, 2026 at 4:00 PM ET.

enGene (NASDAQ:ENGN) last released its quarterly earnings results on Monday, March 9th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.11. On average, analysts expect enGene to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

enGene Stock Performance

Shares of ENGN opened at $1.67 on Thursday. enGene has a 1 year low of $1.40 and a 1 year high of $12.25. The company has a market capitalization of $111.87 million, a price-to-earnings ratio of -0.74 and a beta of -0.30. The company’s 50 day simple moving average is $5.12 and its 200 day simple moving average is $7.51. The company has a debt-to-equity ratio of 0.09, a quick ratio of 11.75 and a current ratio of 11.75.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Cresset Asset Management LLC acquired a new position in enGene in the second quarter valued at $36,000. Paloma Partners Management Co acquired a new stake in enGene during the second quarter worth about $38,000. Raymond James Financial Inc. raised its holdings in shares of enGene by 383.6% in the 3rd quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock worth $68,000 after purchasing an additional 7,932 shares during the period. Citadel Advisors LLC raised its holdings in shares of enGene by 153.3% in the 3rd quarter. Citadel Advisors LLC now owns 58,370 shares of the company’s stock worth $399,000 after purchasing an additional 35,327 shares during the period. Finally, Millennium Management LLC lifted its stake in shares of enGene by 57.3% in the 3rd quarter. Millennium Management LLC now owns 20,502 shares of the company’s stock valued at $140,000 after purchasing an additional 7,472 shares in the last quarter. 64.16% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms recently commented on ENGN. Wells Fargo & Company reiterated an “equal weight” rating and issued a $2.00 target price (down from $25.00) on shares of enGene in a research note on Friday, May 8th. Raymond James Financial cut enGene from a “strong-buy” rating to an “outperform” rating and set a $4.00 price target for the company. in a report on Friday, May 8th. Wall Street Zen downgraded shares of enGene from a “hold” rating to a “sell” rating in a research note on Saturday, April 18th. Leerink Partners lowered shares of enGene from an “outperform” rating to a “market perform” rating and set a $2.00 price objective on the stock. in a report on Friday, May 8th. Finally, Weiss Ratings cut shares of enGene from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 15th. Four equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $12.68.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.